These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25286758)

  • 1. Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status.
    Nadal R; Salido M; Nonell L; Rodríguez-Rivera M; Puigdecanet E; Garcia-Puche JL; Macià M; Corominas JM; Serrano MJ; Lorente JA; Solé F
    Tumour Biol; 2015 Feb; 36(2):711-8. PubMed ID: 25286758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
    Paoletti C; Cani AK; Larios JM; Hovelson DH; Aung K; Darga EP; Cannell EM; Baratta PJ; Liu CJ; Chu D; Yazdani M; Blevins AR; Sero V; Tokudome N; Thomas DG; Gersch C; Schott AF; Wu YM; Lonigro R; Robinson DR; Chinnaiyan AM; Bischoff FZ; Johnson MD; Park BH; Hayes DF; Rae JM; Tomlins SA
    Cancer Res; 2018 Feb; 78(4):1110-1122. PubMed ID: 29233927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome‑wide copy number analysis of circulating tumor cells in breast cancer patients with liver metastasis.
    Zou L; Imani S; Maghsoudloo M; Shasaltaneh MD; Gao L; Zhou J; Wen Q; Liu S; Zhang L; Chen G
    Oncol Rep; 2020 Sep; 44(3):1075-1093. PubMed ID: 32705227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of copy number and loss of heterozygosity in primary breast carcinomas using high-density SNP array.
    Ching HC; Naidu R; Seong MK; Har YC; Taib NA
    Int J Oncol; 2011 Sep; 39(3):621-33. PubMed ID: 21687935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma.
    Marescalco MS; Capizzi C; Condorelli DF; Barresi V
    J Oral Pathol Med; 2014 Jan; 43(1):20-7. PubMed ID: 23750501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
    Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic imbalance at an 8q24 oncogenic SNP is involved in activating MYC in human colorectal cancer.
    Sugimachi K; Niida A; Yamamoto K; Shimamura T; Imoto S; Iinuma H; Shinden Y; Eguchi H; Sudo T; Watanabe M; Tanaka J; Kudo S; Hase K; Kusunoki M; Yamada K; Shimada Y; Sugihara K; Maehara Y; Miyano S; Mori M; Mimori K
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S515-21. PubMed ID: 24390711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
    Pestrin M; Salvianti F; Galardi F; De Luca F; Turner N; Malorni L; Pazzagli M; Di Leo A; Pinzani P
    Mol Oncol; 2015 Apr; 9(4):749-57. PubMed ID: 25539732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of genomic signatures in circulating tumor cells from breast cancer.
    Kanwar N; Hu P; Bedard P; Clemons M; McCready D; Done SJ
    Int J Cancer; 2015 Jul; 137(2):332-44. PubMed ID: 25529931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer.
    Takatsuno Y; Mimori K; Yamamoto K; Sato T; Niida A; Inoue H; Imoto S; Kawano S; Yamaguchi R; Toh H; Iinuma H; Ishimaru S; Ishii H; Suzuki S; Tokudome S; Watanabe M; Tanaka J; Kudo SE; Mochizuki H; Kusunoki M; Yamada K; Shimada Y; Moriya Y; Miyano S; Sugihara K; Mori M
    Ann Surg Oncol; 2013 Apr; 20(4):1395-402. PubMed ID: 22976378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
    Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
    Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.
    Fang M; Toher J; Morgan M; Davison J; Tannenbaum S; Claffey K
    Cancer; 2011 May; 117(10):2024-34. PubMed ID: 21523713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.
    Koch C; Kuske A; Joosse SA; Yigit G; Sflomos G; Thaler S; Smit DJ; Werner S; Borgmann K; Gärtner S; Mossahebi Mohammadi P; Battista L; Cayrefourcq L; Altmüller J; Salinas-Riester G; Raithatha K; Zibat A; Goy Y; Ott L; Bartkowiak K; Tan TZ; Zhou Q; Speicher MR; Müller V; Gorges TM; Jücker M; Thiery JP; Brisken C; Riethdorf S; Alix-Panabières C; Pantel K
    EMBO Mol Med; 2020 Sep; 12(9):e11908. PubMed ID: 32667137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.